Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Wacker Neuson FY11 Profit Rises - Quick Facts

Wacker Neuson SE (WKRCF.PK) posted fiscal 2011 consolidated earnings of 85.8 million euros or 1.22 euros per share versus 23.9 million euros or 0.34 euros per share last year.

EBITDA for the year rose to 162.6 million euros from 77.8 million euros in the prior year.

Revenue improved year-over-year to 991.6 million euros from 757.9 million euros.

Looking forward, assuming market trends remain positive, the Executive Board predicts overall revenue for fiscal 2012 of around 1.1 billion euros and an EBITDA margin of at least 15 percent. It also expects double-digit revenue growth in 2013, with the same high levels of profitability

Click here to receive FREE breaking news email alerts for Wacker Neuson SE and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Denis Mukwege, a doctor from the Democratic Republic of Congo, has won this year's Sakharov Prize for Freedom of Thought for helping thousands of gang rape victims in the country. The award was instituted by the European Parliament, and the laureate for 2014 was selected by EP President Martin Schulz and the political group leaders. Announcing Europe's top human rights prize Tuesday, Schulz said Stocks moved sharply higher over the course of the trading day on Tuesday, extending the recovery from the sell-off seen in recent weeks. The Nasdaq and the S&P 500 closed higher for the fourth consecutive session but remain well off their mid-September highs. Despite indications that the spread of Ebola inside the U.S. has been contained, the results of a new Gallup poll show the deadly disease had made its debut on a list of the top 10 most important problems facing the country.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.